Log In
BCIQ
Print this Print this
 

VX-970

  Manage Alerts
Collapse Summary General Information
Company Vertex Pharmaceuticals Inc.
DescriptionSelective ataxia telangiectasia and Rad3 related (ATR; FRP1) inhibitor
Molecular Target Ataxia telangiectasia and Rad3 related (ATR) (FRP1)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today